BiotechTube

mometasone furoate

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Nasal Polyps

Conditions

Nasal Polyps

Trial Timeline

Jul 1, 2013 → Jan 9, 2018

NCT ID
NCT01616160

About mometasone furoate

mometasone furoate is a approved stage product being developed by Merck for Nasal Polyps. The current trial status is terminated. This product is registered under clinical trial identifier NCT01616160. Target conditions include Nasal Polyps.

What happened to similar drugs?

7 of 20 similar drugs in Nasal Polyps were approved

Approved (7) Terminated (2) Active (12)
✅Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
✅Budesonide NasalJohnson & JohnsonApproved
✅Dupilumab SAR231893SanofiApproved
✅DupilumabSanofiApproved
✅Dupilumab + Omalizumab + PlaceboSanofiApproved
✅Dupilumab Prefilled SyringeRegeneron PharmaceuticalsApproved
✅mometasone furoate nasal spray + placebo nasal sprayOrganonApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01616160ApprovedTerminated

Competing Products

20 competing products in Nasal Polyps

See all competitors
ProductCompanyStageHype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
Rabeprazole 20 mg twice a day for 90-day period treatmentEisaiPhase 2
35
High dose of methotrexate + Gemcitabine + Pegaspargase + DexamethasoneEli LillyPhase 2
31
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
43
xylo+dex nasal spray (0.1 mg+5 mg/dose) + NasicJohnson & JohnsonPhase 3
40
Budesonide NasalJohnson & JohnsonApproved
47
Diphenhydramine hydrochlorideJohnson & JohnsonPhase 1
29
SHR-1210Jiangsu Hengrui MedicinePhase 2
31
Experimental: Tezepelumab + Mometasone furoate or equivalent intranasal corticosteroidAstraZenecaPhase 3
40
Benralizumab 30 mg + Matched placeboAstraZenecaPhase 3
32
Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone FuroateAstraZenecaPhase 3
40
Benralizumab + PlaceboAstraZenecaPhase 3
40
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
42
Fevipiprant 150 mg + Fevipiprant 450 mg + PlaceboNovartisPhase 3
40
Omalizumab + PlaceboNovartisPhase 2
35
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
carfilzomibAmgenPhase 1
29